Tempest Therapeutics

The lead program amezalpat (TPST‑1120), a PPARα antagonist, showed positive Phase 1b/2 data in combination with atezolizumab and bevacizumab in first-line hepatocellular carcinoma patients. It demonstrated a six-month improvement in median overall survival compared to standard of care alone. The FDA provided positive feedback at the end-of-phase 2 meeting supporting the design of an upcoming pivotal global randomized Phase 3 trial planned for Q1 2025[1][2][5][7][9].

TPST‑1495, an oral dual EP2/EP4 antagonist targeting prostaglandin pathways involved in tumor growth and immune suppression, completed monotherapy dose escalation and plans to enter Phase 2 trials for FAP under NCI funding[9].